Personen

TOP 5 Publikationen:

1. Gründer G, Mertens L. Psilocybin for Depression.N Engl J Med. 2021 385(9):863.
2. Schmidt-Kraepelin C, Feyerabend S, Engelke C, Riesbeck M, Meisenzahl-Lechner E, Verde PE, Correll CU, Kluge M, Makiol C, Neff A, Lange C, Englisch S, Zink M, Langguth B, Poeppl TB, Reske D, Gouzoulis-Mayfrank E, Gründer G, Hasan A, Brockhaus-Dumke A, Jäger M, Baumgärtner J, Leucht S, Cordes J, COMBINE Study Group . Amisulpride and olanzapine combination treatment versus each monotherapy in acutely ill patients with schizophrenia in Germany (COMBINE): a double-blind randomised controlled trial.Lancet Psychiatry. 2022 9(4):291-306.
3. Gründer G, Mertens L, Jungaberle A, Jungaberle H, Spangemacher M. Compassionate use of psilocybin for treatment-resistant depression in Germany.Lancet Psychiatry. 2026 13(2):91-93. Epub 2025 Sep 18.
4. Gründer G, Brand M, Mertens L, Jungaberle H, Kärtner L, Scharf DJ, Spangemacher M, Wolff M. Treatment with psychedelics is psychotherapy: beyond reductionism.Lancet Psychiatry. 2024 11(3):231-236. Epub 2023 Dec 12.
5. Mertens L, Betzler F, Brand M, Evens R, Jungaberle A, Jungaberle H, Kärtner L, Majic T, Schmitz C, Ströhle A, Scharf D, Spangemacher M, Wolff M, Assadi Z, Bahri S, Becher L, Färber LV, Harder H, Kirchen N, Kulakova E, Kunz LC, Meijer A, Rohrmoser B, Wellek S, Berger M, Koslowski M, Gründer G. Long-Term Efficacy of Psilocybin with Adjunct Psychotherapy in Treatment-Resistant Major Depression (EPIsoDE): 6- and 12-Month Naturalistic Follow-Up of a Phase 2b Trial.Psychother Psychosom. 2026 May 27. [Epub ahead of print]:1-28.